UK 34787

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526521

CAS#: 72818-36-1

Description: UK 34787 is a thromboxane inhibitor.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-10-31. Prices are subject to change without notice.

UK 34787 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 526521
Name: UK 34787
CAS#: 72818-36-1
Chemical Formula: C15H17N3
Exact Mass: 239.1422
Molecular Weight: 239.322
Elemental Analysis: C, 75.28; H, 7.16; N, 17.56

Synonym: UK 34787, UK-34787, UK34787

IUPAC/Chemical Name: 3-((1H-imidazol-1-yl)methyl)-2-isopropyl-1H-indole


InChi Code: InChI=1S/C15H17N3/c1-11(2)15-13(9-18-8-7-16-10-18)12-5-3-4-6-14(12)17-15/h3-8,10-11,17H,9H2,1-2H3


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Gresele P, Blockmans D, Deckmyn H, Vermylen J. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders. J Pharmacol Exp Ther. 1988 Jul;246(1):301-7. PubMed PMID: 3134542.

2: Heptinstall S, Fox SC. Human blood platelet behaviour after inhibition of thromboxane synthetase. Br J Clin Pharmacol. 1983;15 Suppl 1:31S-37S. PubMed PMID: 6401998; PubMed Central PMCID: PMC1427694.

3: Peacock I, Hawkins M, Heptinstall S. Platelet behaviour in non-insulin-dependent diabetes--influence of vascular complications, treatment and metabolic control. Thromb Haemost. 1986 Jun 30;55(3):361-5. PubMed PMID: 3092392.

4: Heptinstall S, Bevan J, Cockbill SR, Hanley SP, Parry MJ. Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb Res. 1980 Oct 15;20(2):219-30. PubMed PMID: 7193919.

5: Carey F, Haworth D. Thromboxane synthase inhibition: implications for prostaglandin endoperoxide metabolism. II. Testing the 'redirection hypothesis' in an acute intravenous challenge model. Prostaglandins. 1986 Jan;31(1):47-59. PubMed PMID: 3754057.

6: Haworth D, Carey F. Thromboxane synthase inhibition: implications for prostaglandin endoperoxide metabolism. I. Characterisation of an acute intravenous challenge model to measure prostaglandin endoperoxide metabolism. Prostaglandins. 1986 Jan;31(1):33-45. PubMed PMID: 3081969.

7: Hornby EJ, Skidmore IF. Evidence that prostaglandin endoperoxides can induce platelet aggregation in the absence of thromboxane A2 production. Biochem Pharmacol. 1982 Mar 15;31(6):1158-60. PubMed PMID: 7200773.